Abstract

The Evaluation of the Role of Inflammation in non-pulmonary disease manifestations in Chronic Airways project (ERICA), funded by the Technology Strategy Board, aims to take research into chronic obstructive pulmonary disease (COPD) forward by studying the effects of inflammation in disease. The objective of the ERICA project is to relate systemic inflammation, defined by elevated fibrinogen, to non-pulmonary disease manifestations in COPD identified by candidate bedside biomarkers of cardiovascular and muscle function.

Mission

The overarching aim of ERICA is to relate systemic inflammation, defined by an elevated fibrinogen, to non-pulmonary disease manifestations in COPD identified by candidate bedside biomarkers of cardiovascular and muscle function. The project will extend the understanding of these biomarkers through cross-sectional evaluation of subjects recruited from existing well-characterized cohorts in the United Kingdom and using experimental medicine hypothesis-testing trials in patients with evidence of systemic inflammation. The impact of this work will be twofold: (i) generating evidence on stratification and efficacy biomarkers to facilitate the design of smaller, more efficient Phase I-III clinical trials of
medicines targeting inflammatory COPD subsets, thereby reducing attrition of new medicines; and (ii)
supporting the development of two specific therapies, thus validating a stratified medicine approach.

**Financing**

Funded by the Technology Strategy Board

http://cctu.medschl.cam.ac.uk/erica

**Sponsors & Partners**

GlaxoSmithKline
The University of Nottingham
Cardiff University
The Royal Brompton Hospital (Imperial College London)
Cambridge University
The University of Edinburgh

Updated: **04/15/2016**